According to Fortune Business Insights, the global liquid biopsy market size was valued at USD 11.66 billion in 2025 and is projected to grow from USD 14.23 billion in 2026 to USD 106.49 billion by 2034, registering a CAGR of 28.61% during the forecast period. North America dominated the market with a 54.57% share in 2025.
Liquid biopsy is emerging as an important technology in modern healthcare because it provides a minimally invasive approach for detecting and monitoring cancer through biological samples such as blood. Unlike conventional tissue biopsies, liquid biopsy can support repeated testing and provide information related to tumor characteristics, treatment response, disease progression, and drug resistance.
Rising Adoption in Oncology
The increasing global burden of cancer is one of the major factors supporting the growth of the liquid biopsy market. Conventional tissue biopsies can be invasive and may require substantial time for sample collection and analysis. Liquid biopsy offers an alternative approach that can help identify circulating tumor DNA and other biomarkers.
The technology is increasingly being explored for cancer screening, diagnosis, prognosis, treatment selection, and monitoring of residual disease. Growing investments in precision medicine and molecular diagnostics are further encouraging healthcare providers and researchers to adopt liquid biopsy solutions.
Kits and Reagents Lead Market Growth
Based on product, the market is segmented into kits & reagents and instruments. Kits & reagents are expected to remain a leading segment during the forecast period. Increasing product launches, regulatory approvals, and adoption of assays for circulating tumor DNA (ctDNA) and non-invasive prenatal testing are contributing to segment expansion.
The application landscape includes oncology, non-invasive prenatal testing (NIPT), and others. According to Fortune Business Insights, the NIPT segment is expected to hold a dominant share in 2026, while oncology remains an important area of application due to the growing demand for advanced cancer detection and monitoring technologies.
North America Dominates the Global Market
North America accounted for 54.57% of the global liquid biopsy market in 2025, generating approximately USD 6.36 billion. The region's strong position is supported by advanced healthcare infrastructure, substantial research and development investments, product innovations, and increasing adoption of precision oncology.
Asia Pacific is also expected to experience strong growth during the forecast period. The region generated approximately USD 2.13 billion in 2025, representing an 18.22% global market share. Rising demand for predictive screening, increasing healthcare investment, and growing awareness of advanced diagnostic technologies are expected to support regional expansion.
Technological Advancements Create New Opportunities
Continuous innovation in molecular diagnostics is creating new opportunities for liquid biopsy providers. Companies are developing highly sensitive assays capable of detecting genetic alterations and monitoring cancer progression from blood samples.
For example, Illumina launched a second version of its TruSight Oncology 500 ctDNA kit in 2023 to support genomic profiling of solid tumors, while Guardant Health has developed blood-based testing solutions for monitoring residual disease and cancer recurrence.
Increasing collaborations between diagnostic companies, pharmaceutical organizations, research institutions, and healthcare providers are also expected to accelerate the development and commercialization of liquid biopsy technologies.
Competitive Landscape
The global liquid biopsy market features several established healthcare and diagnostics companies. Major players include Guardant Health, Personalis, Foundation Medicine, Natera, Illumina, F. Hoffmann-La Roche, Menarini Silicon Biosystems, Thermo Fisher Scientific, QIAGEN, and Bio-Rad Laboratories. These companies are focusing on product development, clinical research, regulatory approvals, and strategic collaborations to strengthen their market positions.
Get Free Sample PDF: https://www.fortunebusinessinsights.com/liquid-biopsy-market-102506
Future Outlook
The liquid biopsy market is expected to witness significant expansion as healthcare systems increasingly prioritize early cancer detection, precision medicine, and minimally invasive diagnostic approaches. Improvements in biomarker detection, growing clinical evidence, and expanding applications beyond oncology could further broaden the technology's potential.
With the market projected to reach USD 106.49 billion by 2034, liquid biopsy is positioned to become an increasingly important component of the global diagnostics and precision medicine landscape. Explore Japan’s Market Opportunities - Latest -Liquid Biopsy Market- Insights